Skip to main content
Click here to get access to our Free Course on Momentum Investing Strategy

NSE · WINDLAS

WINDLAS

HealthcarePharmaceuticals & Biotechnology₹2040 cr market cap
₹979.25 ▼ -0.95% today As of 19 Nov 2026
52-week low ₹705.7552-week high ₹1154.75

-14.4% from the 52-week high · +40.1% above the low

Windlas Biotech Ltd. operates as a contract development and manufacturing organization (CDMO). The firm provides a range of contract development and manufacturing organization (CDMO) services ranging from product discovery, product development, licensing and commercial manufacturing of generic products, including complex generics. Its therapeutic categories, such as, anti-diabetic, cardiovascular, neuropsychiatry and respiratory therapies. The Company’s service capabilities include formulation development, technology scale-up and full-scale commercial manufacturing. The company has capabilities for both solid and liquid pharmaceutical dosage forms. The firm markets its own manufactured nutraceutical, pharmaceutical and ayurvedic products to serve the semi-urban and rural communities. The company also has a salesforce and distribution network spread across over 14 states. The Company’s manufacturing facilities are located at Dehradun in Uttarakhand.

The short version. WINDLAS reported revenue of ₹238 crore for Mar 2026, up 17.2% from a year earlier. Net profit was ₹16 crore (up 0.0% year on year). Return on equity was 11.4% in Mar 2026. Promoter holding was 63.31% in Sep 2026, up 0.80 points over 8 quarters.

1 · The price

How has the stock traded?

WINDLAS trades 14.4% below its 52-week high and 40.1% above its 52-week low.

Change over period: —

1M+9.1%
3M+2.5%
6M+23.9%
1Y+22.4%

2 · The business

Is it growing?

Sales, year on year+17.2%

Mar 2026 revenue of ₹238 cr.

Profit, year on year+0.0%

Mar 2026 net profit of ₹16 cr.

Net margin6.7%

1.3 pts lower than a year earlier.

3-year growth16.0% profit

Revenue compounded at 20.8% over the same 3 years.

Reported results · ₹ crore

Revenue and profit

Show the numbers

Quarterly

Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024
Revenue238233222210203195187175
Net profit1615181816161613
Net margin %6.76.48.08.48.08.08.47.7
EPS (₹)7.587.128.458.437.777.457.496.45

Annual

FY2026FY2025FY2024FY2023FY2022
Revenue904760631513466
Net profit6661584338
Net margin %7.48.09.28.38.1
EPS (₹)31.4929.127.9820.3517.39

3 · The quality

How well does it turn capital into profit?

Return on equity was 11.4% in Mar 2026; debt to equity is 0.05.

Profitability · 4 years

Returns and margins

Mar 2026Mar 2025Mar 2024Mar 2023
Return on equity %11.412.112.910.6
Return on capital %15.716.517.214.2
EBITDA margin %13.314.414.213.4
Net margin %7.27.89.08.2

Compound growth

Revenue vs profit

3 years5 years
Revenue CAGR20.8%—
Profit CAGR16.0%—
Debt to equity0.05
Interest cover19.0x
Current ratio1.95
P/E ratio31.6

4 · The owners

Who holds it, and are they adding?

Promoter holding63.31%

Up 0.8 pts over 8 quarters.

Foreign institutions2.08%

Up 0.53 pts over 8 quarters.

Domestic institutions7.24%

Down 3.02 pts over 8 quarters.

Mutual fund schemes5

+0 versus the previous month.

Shareholding pattern (%)

Quarter by quarter

Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026Sep 2026Change
Promoter62.5162.3462.3461.9961.9961.963.3163.31+0.8
FII1.551.521.441.110.930.62.042.08+0.53
DII10.2610.8911.2111.4311.4411.819.847.24-3.02
Public25.6825.2525.0125.4725.6425.724.827.36+1.68

Mutual fund holdings · Oct 2026

5 schemes hold this stock

5 the month before.

  • UTI - Healthcare Fund1.27% of NAV
  • ICICI Prudential Healthcare Fund0.44% of NAV
  • Bandhan Small Cap Fund0.05% of NAV
  • Motilal Oswal BSE Healthcare ETF0.04% of NAV
  • Bandhan BSE Healthcare Index Fund0.04% of NAV

See what mutual funds are buying

5 · The model view

What does our factor model say?

Factor scores, model flags and screen results for WINDLAS are part of the Wright portfolio review.

Run your free portfolio review

Watchouts

What to review

Model flags are shown inside the portfolio review, alongside your other holdings.

Model ratingLocked
Factor betaLocked
VolatilityLocked

Quick answers

Common questions about WINDLAS

What is the WINDLAS share price?

WINDLAS (WINDLAS) last closed at ₹979.25, down 0.95% on the day. Its 52-week range is ₹705.75 to ₹1,154.75.

What is the market cap of WINDLAS?

WINDLAS has a market capitalisation of about ₹2,040 crore. Its price-to-earnings ratio is 31.6.

How are WINDLAS's latest results?

WINDLAS reported revenue of ₹238 crore for Mar 2026, up 17.2% from a year earlier. Net profit was ₹16 crore (up 0.0% year on year). Return on equity was 11.4% in Mar 2026. Promoter holding was 63.31% in Sep 2026, up 0.80 points over 8 quarters.

Who owns WINDLAS?

As of Sep 2026, shareholding was: Promoter 63.31%, FII 2.08%, DII 7.24%, Public 27.36%.

How many mutual funds hold WINDLAS?

5 mutual fund schemes held WINDLAS in October 2026. That compares with 5 the month before.

Corporate actions

Recent dividends, bonuses and splits

  • 21 Jul 2025 · Final Dividend - Rs. 5.8
  • 17 Sep 2024 · Dividend - Rs. 5.5
  • 05 Sep 2023 · Final Dividend - Rs. 4
  • 09 Sep 2022 · Dividend - Rs. 3.5

Financials are as reported by the company (consolidated), in ₹ crore. Source: FinEdge exchange filings feed. Figures can differ from other sites because of one-off items and restatements. Callouts above are arithmetic on reported data, not recommendations.

Research data on this page is provided under Wright Research's SEBI Research Analyst registration. The Terms & Conditions of our Research Analyst services apply.